Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.03 and last traded at C$0.04, with a volume of 4090 shares trading hands. The stock had previously closed at C$0.03.
Kane Biotech Stock Performance
The company has a quick ratio of 0.39, a current ratio of 0.68 and a debt-to-equity ratio of -308.66. The firm has a market capitalization of C$6.36 million, a P/E ratio of -1.75 and a beta of 1.03. The firm has a 50 day moving average of C$0.03 and a 200-day moving average of C$0.04.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Further Reading
- Five stocks we like better than Kane Biotech
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
